Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Episode 6: See you at the next meeting? The intersection of medicine and politics

Episode 6: See you at the next meeting? The intersection of medicine and politics

FromThe View on GU | with Lalani and Wallis


Episode 6: See you at the next meeting? The intersection of medicine and politics

FromThe View on GU | with Lalani and Wallis

ratings:
Length:
25 minutes
Released:
Apr 23, 2024
Format:
Podcast episode

Description

In Episode 6, Drs. Aly-Khan Lalani and Christopher Wallis are joined by The View on GU’s first guest Dr. Diana Magee to discuss why location matters when it comes to medical conferences. They touch upon Dr. Magee’s recent article in The Journal of Urology, and consider the ethical, economic and political implications of the upcoming American Urological Association conference in Texas following implementation of the state’s abortion ban. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practicing clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: https://theviewongu.com
This podcast has been made possible through financial support by Bristol Myers Squibb, Merck, and TerSera.
Released:
Apr 23, 2024
Format:
Podcast episode

Titles in the series (11)

There is currently a lack of organic multi-disciplinary discussion on what is truly impactful to the field of genitourinary (GU) cancers. The View on GU with Lalani and Wallis is a podcast that will integrate key clinical data from major conferences and high impact publications into meaningful take home messages for practicing clinicians. Importantly, Lalani and Wallis will also discuss the impact of governmental approvals and funding considerations on the GU oncology treatment landscape and provide practical considerations on the management of patients on new-to-market therapies.